Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
| ▸ | CDC42 | P60953 | 1/20 | 0.50 |
| ▸ | RAC1 | P63000 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 3/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7958317 | 1.00 | GPR88 (0.62) | GPR88SMN1; SMN2PTGS2AKR1C3AKR1C2 | |
| SCHEMBL7960070 | 0.84 | GPR88 (0.59) | GPR88SMN1; SMN2PTGS2AKR1C3AKR1C2 | |
| SCHEMBL6481469 | 0.84 | SMN1; SMN2 (0.52) | GPR88SMN1; SMN2PTGS2AKR1C3AKR1C2 | |
| SCHEMBL4156225 | 0.81 | MME (0.64) | GPR88SMN1; SMN2MME | |
| SCHEMBL7960075 | 0.81 | GPR88 (0.59) | GPR88MME | |
| SCHEMBL599316 | 0.81 | PTGS2 (0.71) | GPR88PTGS2AKR1C3AKR1C2PTGS1 | |
| SCHEMBL350067 | 0.81 | PTGS2 (0.71) | GPR88PTGS2AKR1C3AKR1C2PTGS1 | |
| SCHEMBL2370631 | 0.81 | PTGS2 (0.71) | GPR88PTGS2AKR1C3AKR1C2PTGS1 | |
| SCHEMBL7960115 | 0.80 | GPR88 (0.57) | GPR88AKR1C3AKR1C2GAAKMT2A | |
| SCHEMBL28662721 | 0.79 | PTGS2 (0.69) | GPR88PTGS2AKR1C3AKR1C2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705050-B2 | Amides, useful in the inhibition of IL-8-induced chemotaxis of neutrophils | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2010-04-27 | — | — | US | disclosed |
| EP-1255726-B1 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS | DOMPE PHA R MA SPA RES & MFG (IT) | 2009-11-11 | — | — | EP | disclosed |
| US-20040181073-A1 | Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2004-09-16 | — | — | US | disclosed |
| EP-1255726-A2 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS | Dompé S.P.A. (IT) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001058852-A2 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8-INDUCED CHEMIOTAXIS OF NEUTROPHILS | Dompé S.p.A. (IT) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040181073-A1 | Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils | CXCL8, MMP8, CCR8 | GPR88 51/4885SMN1; SMN2 3442/4885PTGS2 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.